US FDA Approves Daraxonrasib, a Breakthrough Treatment for Pancreatic Cancer

Pancreatic cancer is notoriously difficult to treat – it is often detected late, spreads quickly, and has resisted most conventional therapies. The approval of daraxonrasib (brand name to be announced) marks only the second new drug specifically for pancreatic cancer in over a decade.

The drug targets tumors harboring the KRAS G12C mutation, which occurs in about 10-15% of pancreatic cancer patients. In a Phase 3 trial, patients receiving daraxonrasib lived a median of 18.5 months versus 9.7 months on standard chemotherapy – a near doubling of survival. The FDA granted accelerated approval based on the trial’s primary endpoint of progression-free survival; a confirmatory study is ongoing.

Dr. Elena Vasquez, a pancreatic cancer specialist at MD Anderson Cancer Center, told the BBC: “This is a genuine game-changer for a subset of patients who previously had almost no options. It’s proof that precision medicine can work even in the toughest cancers.”

However, experts caution that daraxonrasib is not a cure and is only effective in patients with the specific KRAS mutation, meaning the majority of pancreatic cancer patients will not benefit. Side effects include liver enzyme elevations, fatigue, and gastrointestinal issues; serious adverse events occurred in about 15% of trial participants.

Patient advocacy groups have welcomed the approval but stress the importance of affordable access. “We need to ensure that this drug reaches the people who need it, regardless of their insurance or income,” said Mark Tilden of the Pancreatic Cancer Action Network.

The drug’s developer, a mid-sized biotech firm, has not yet announced pricing, though analysts expect it to be in line with other targeted cancer therapies, which can cost $150,000 to $200,000 per year.

Why This Matters

Pancreatic cancer is among the deadliest cancers, with a five-year survival rate below 10%. Any meaningful treatment advance has the potential to save thousands of lives annually.
The approval validates the strategy of targeting KRAS mutations, which were long considered “undruggable.” This could open the door for similar drugs in other KRAS-driven cancers.
Patients with the G12C mutation, who previously faced a grim prognosis, now have a viable option that nearly doubles their median survival time.

Background

Pancreatic cancer has been a graveyard for drug development. The standard chemotherapy regimen, FOLFIRINOX, was approved in 2011 and adds only a few months of survival. Dozens of targeted therapies and immunotherapies have failed in late-stage trials. In 2022, the first KRAS G12C inhibitor, sotorasib, was approved for lung cancer but showed only modest activity in pancreatic cancer. Daraxonrasib is a next-generation inhibitor designed to bind more potently to the mutant protein. The FDA’s decision comes after a priority review and breakthrough therapy designation.

Key Perspectives

Patients with KRAS G12C mutation: For this group, daraxonrasib offers a substantial survival benefit and a new treatment option where none existed before. Advocacy groups emphasize the need for genetic testing to identify eligible patients.

Oncologists: Many view the approval as a validation of precision oncology for pancreatic cancer. However, they caution that the drug is not a cure and that resistance may develop over time, requiring combination strategies.

Critics and skeptics: Some question the durability of the benefit given that the confirmatory trial is still ongoing. Others raise concerns about cost and accessibility, particularly for uninsured or underinsured patients. There is also the reality that the majority of pancreatic cancer patients (those without the G12C mutation) are left without a new option.

What to Watch

Pricing and insurance coverage decisions from the manufacturer and payers, which will determine real-world access.
Results of the confirmatory Phase 3 trial expected within two years; any negative findings could lead to a withdrawal of accelerated approval.
Development of combination therapies (e.g., with immunotherapy or chemotherapy) that might expand the drug’s efficacy or delay resistance.

ZOTPAPER